Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Provides Update on Common Share Private Placement

June 19, 2024


BURLINGTON, Ontario – June 17, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...

Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application

May 29, 2024


BURLINGTON, Ontario – May 29, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled “Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in...

Rapid Dose Therapeutics and McMaster University’s Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery

May 22, 2024


Burlington, Ontario – May 22, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE in partnership with McMaster University (“McMaster”) is pleased to announce the publication of the results of their collaborative research...

Rapid Dose Announces Closing of Fifth Tranche of Private Placement of Units

May 16, 2024


BURLINGTON, Ontario – May 16, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $250,000 in a fifth tranche of its previously announced private placement financing (the “Financing”), bringing the total amount raised to $1,960,000. ...

Rapid Dose Provides Update on Common Share Private Placement

May 9, 2024


BURLINGTON, Ontario – May 8, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated March 25, 2024, announcing a proposed equity private placement financing (the “Financing”), the Company has received an extension from...

Rapid Dose Announces Closing of Fourth Tranche of Equity Private Placement Financing

April 16, 2024


BURLINGTON, Ontario – April 15, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $300,000 in a fourth tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...

Rapid Dose Announces Closing of Third Tranche of Equity Private Placement Financing

April 3, 2024


BURLINGTON, Ontario – April 3, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $110,000 in a third tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...

Payment in Shares for Interest on Secured Debt

April 1, 2024


BURLINGTON, Ontario – April , 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...

Rapid Dose Announces Proposed Equity Private Placement Financing

March 25, 2024


BURLINGTON, Ontario – March 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $6,000,000 of gross proceeds, consisting of up to 35,294,117 common shares...

Rapid Dose Announces Cancellation of Stock Options and Intention to Regrant

February 29, 2024


BURLINGTON, Ontario – February 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that effective February 28, 2024 (the “Effective Date”), the Company has cancelled an aggregate of 5,350,000 stock options (“Options”) to purchase common shares of the Company...

1 2 3 4 5 6 7 8 9 10 11 15